Company

Abeona Therapeutics Inc.

Headquarters: New York, NY, United States

Employees: 76

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

NASDAQ: ABEO +0.70%

Market Cap

$186.0 Million

USD as of July 1, 2024

Market Cap History

Abeona Therapeutics Inc. market capitalization over time

Evolution of Abeona Therapeutics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Abeona Therapeutics Inc.

Detailed Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Abeona Therapeutics Inc. has the following listings and related stock indices.


Stock: NASDAQ: ABEO wb_incandescent

Stock: FSX: PCJP wb_incandescent

Details

Headquarters:

1330 Avenue of the Americas

33rd Floor

New York, NY 10019

United States

Phone: 646 813 4701